A Phase 4 interventional study of Dapagliflozin in ACS (Acute Coronary Syndrome) and SGLT2 Inhibitors, sponsored by Shenyang Northern Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Shenyang Northern Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital — 5 open to participants now, 5 under way, none of them phase 3. Acute Coronary Syndrome · Shenyang Northern Hospital.
Among the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital, this one is one of 3 that started in 2026, is one of 8 in phase 4, and was the 10th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →5 of the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital are open now, in 1 country. Recruiting first, the newest first:
Shenyang Northern Hospital · Sites in China
Ages 18–80
Shenyang Northern Hospital · Sites in China
Ages 18+
Shenyang Northern Hospital
Ages 18+
Shenyang Northern Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is below the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 723 across the 8 interventional studies, 2,500 across the 2 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shenyang Northern Hospital is the lead sponsor of 42 studies on the registry; 11 are open to participants now.
2 of the studies in Acute Coronary Syndrome by Shenyang Northern Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06216821Shenyang Northern HospitalOPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time | 2026-12-31 |
| NCT07351643Shenyang Northern HospitalCCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this clinical trial is to investigate whether dapagliflozin (a sodium-glucose cotransporter 2 inhibitor, SGLT2i) can reduce levels of coronary inflammation in patients with stage 4 CKM syndrome.
Coronary inflammation will be measured using the fat attenuation index (FAI), a marker derived from coronary CT angiography (CCTA) that quantifies inflammation in the fat tissue surrounding heart arteries.
The main questions it aims to answer are
Researchers will compare participants who take dapagliflozin 10 mg daily plus standard therapy to those who receive standard therapy alone for 6 months.
Participants will:
Patients with stage 4 CKM syndrome are individuals who have at least one of excessive/dysfunctional adiposity, other CKM-related risk factors, or chronic kidney disease (CKD), complicated by clinical cardiovascular disease (CVD), including coronary artery disease, heart failure, stroke, peripheral arterial disease, and atrial fibrillation. Stage-4 CKM patients carry an extremely high risk of adverse clinical outcomes. Nearly 80 % of adults in China are at stage 1 or higher of CKM syndrome, among whom patients at stage 4 exhibit a 4-fold higher mortality risk compared with those at stage 0. Representing a very-high-risk population, they are in urgent need of targeted interventions.
Chronic inflammation constitutes the core pathological mechanism underlying CKM progression. Circulating inflammatory biomarkers currently lack sufficient specificity, while PET-CT is costly and poorly accessible, limiting its clinical utility. Studies have demonstrated that fat attenuation index (FAI), calculated by analyzing the radiodensity of pericoronary adipose tissue (PCAT) derived from coronary computed-tomographic angiography (CCTA), enables non-invasive quantification of coronary inflammation. In the setting of arterial inflammation, PCAT loses lipid content with an elevated water-to-lipid ratio, shifting FAI from the lipid-rich phase (approximately -190 HU) toward the water-rich phase (approximately -30 HU). As a novel surrogate inflammatory biomarker, PCAT holds promise as a new therapeutic target for cardiovascular diseases.
Beyond their glucose-lowering and diuretic effects, sodium-glucose cotransporter 2 inhibitors (SGLT2is) exert anti-inflammatory properties, including suppression of inflammatory-cytokine expression and mitigation of oxidative stress. They also reduce the thickness and volume of epicardial adipose tissue (EAT) and dampen its secretion of inflammatory cytokines, which may represent an important pathway mediating their cardiovascular benefits. Nevertheless, existing studies enroll relatively homogeneous populations and do not cover the high-risk stage-4 CKM cohort. Patients with stage-4 CKM have greater EAT burden, and EAT contributes to disease progression. Accordingly, leveraging photon-counting CT, this study aims to explore the modulatory effect of 6-month SGLT2i therapy on local coronary inflammation in stage-4 CKM patients, as well as the association between clinical benefits and alleviated coronary inflammation, so as to provide theoretical evidence for targeted anti-inflammatory therapy in this patient population.
The criteria were revised on the registry on Oct 30, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive dapagliflozin 10 mg orally once daily in addition to guideline-directed medical therapy for 6 months.
Drug: Dapagliflozin
Participants receive guideline-directed medical therapy alone without any SGLT2 inhibitor for 6 months.
10 mg/d for 6 months
Changes in FAI from baseline to 6 months in patients assessed by CCTA
Change in FAI of major coronary arteries (left main \[LM\], right coronary artery \[RCA\], left anterior descending \[LAD\], and left circumflex \[LCX\]) from baseline to 6 months, expressed in Hounsfield Units (HU), assessed at the patient level.
Time frame: From randomization to 6 months post-randomization
Change in total plaque volume
Absolute change in total coronary plaque volume (mm³)
Time frame: From randomization to 6 months post-randomization
Change in calcified plaque volume
Absolute change in calcified plaque volume (mm³)
Time frame: From baseline (at randomization) to 6 months post-randomization
Change in fibrous plaque volume
Absolute change in fibrous plaque volume (mm³)
Time frame: From baseline (at randomization) to 6 months post-randomization
Change in fibrofatty plaque volume
Absolute change in fibrofatty plaque volume (mm³)
Time frame: From baseline (at randomization) to 6 months post-randomization
Change in low-attenuation plaque volume
Absolute change in low-attenuation plaque volume (mm³)
Time frame: From baseline (at randomization) to 6 months post-randomization
Change in coronary stenosis
Absolute change in degree of coronary artery stenosis (%)
Time frame: From baseline (at randomization) to 6 months post-randomization
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 12 months is below that.
Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Feb 2026 → Jun 2026, primary completion Oct 2026 → Jun 2027 and completion Dec 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin
Shenyang Northern Hospital